Table 1.
Characteristics of the included studies.
| NO. | Author | Year | Duration of experiment | Count | Count (F/M) | Intervention | Age | Outcomes | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Observation | Control | Observation | Control | Observation | Control | Observation | Control | |||||
| 1 | Wu YL | 2014 | 2011.10–2013.10 | 32 | 30 | 18/14 | 17/13 | Icotinib + WBRT | WBRT | 60–86 | 61–87 | ①②③④⑤⑥ |
| 2 | Zheng Xiao-Ke | 2016 | 2011.11–2013.11 | 38 | 38 | 20/18 | 21/17 | Icotinib + WBRT | WBRT | 55–85 | 56–87 | ①②③④⑥ |
| 3 | XIA Yun | 2017 | 2014.3–2016.3 | 20 | 20 | 7/13 | 6/14 | Icotinib + WBRT | WBRT | 35–76 | 34–75 | ①②③④⑤ |
| 4 | JI Rong | 2019 | 2013.6–2017.6 | 23 | 21 | 13/10 | 12/9 | Icotinib + WBRT | WBRT | 49–70 | 49–74 | ①②③④⑤⑥⑦ |
| 5 | Ge T | 2020 | 2018.6–2019.9 | 48 | 48 | 22/26 | 24/24 | Icotinib + WBRT | WBRT | 52.9 ± 7.1 | 52.7 ± 6.9 | ①②③④⑤⑥⑦ |
| 6 | Wang C | 2020 | 2016.6–2019.6 | 50 | 50 | 22/28 | 21/29 | Icotinib + WBRT | WBRT | 64.62 ± 3.44 | 64.59 ± 3.41 | ①②④⑥ |
| 7 | LI Wenge | 2020 | 2013.2–2016.2 | 51 | 40 | 25/26 | 22/18 | Icotinib + WBRT | WBRT | / | / | ①②③④⑤⑦ |
| 8 | Liu B | 2021 | 2019.4–2020.4 | 35 | 35 | 15/20 | 14/21 | Icotinib + WBRT | WBRT | 67.89 ± 5.68 | 65.71 ± 5.51 | ①②④⑤⑥ |
| 9 | Lu XY | 2021 | 2016.1–2017.12 | 30 | 30 | 11/19 | 12/18 | Icotinib + WBRT | WBRT | 59.3 ± 2.2 | 59.2 ± 2.1 | ①②④⑥⑦ |
| 10 | Huang WB | 2021 | 2018.1–2020.1 | 39 | 39 | 18/21 | 16/23 | Icotinib + WBRT | WBRT | 62.4 ± 2.3 | 62.8 ± 2.5 | ③④ |
① Response rate; ② Disease control rate; ③ Rash; ④ Adverse reaction in gastrointestinal tract; ⑤ Hepatic injury; ⑥ Leukopenia; ⑦ PFS, progression free survival; WBRT, whole brain radiotherapy.
F = female, M = male.